MIGUEL ORTEGA: Open Payments
NPI 1023775939 · CLAREMONT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$735 in 22 payments from 11 companies in 2025. Trend: 2023 $248 · 2024 $1,062 · 2025 $735
Food & beverage: $735
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 2 | $163 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Teva Pharmaceuticals USA, Inc. | 4 | $87 |
| Janssen Pharmaceuticals, Inc | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Sage Therapeutics, LLC | 1 | $26 |
Products named: LYBALVI, Auvelity, CAPLYTA, AUSTEDO XR, INVEGA SUSTENNA, REXULTI, COBENFY, ARISTADA.
Industry payments across CA — which companies pay providers there.
